Edition:
India

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

9.76USD
7 Jul 2020
Change (% chg)

$0.26 (+2.74%)
Prev Close
$9.50
Open
$9.65
Day's High
$9.97
Day's Low
$9.50
Volume
20,808
Avg. Vol
144,545
52-wk High
$15.00
52-wk Low
$2.09

Latest Key Developments (Source: Significant Developments)

Alpine Reports Qtrly Loss Per Share Of $0.30
Friday, 15 May 2020 

May 14 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE.ALPINE IMMUNE SCIENCES INC - EXPECTS TO HAVE SUFFICIENT CASH TO FUND ITS PLANNED OPERATIONS FOR AT LEAST NEXT 12 MONTHS.ALPINE IMMUNE SCIENCES INC QTRLY LOSS PER SHARE $0.30.  Full Article

Alpine Immune Sciences Says Q4 Loss Per Share Of $0.33
Tuesday, 31 Mar 2020 

March 30 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES - AS OF DECEMBER 31, 2019, WE HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH, AND SHORT-TERM INVESTMENTS TOTALING $40.9 MILLION.ALPINE IMMUNE SCIENCES INC QTRLY LOSS PER SHARE OF $0.33.  Full Article

Alpine Immune Sciences’ Alpn-101 Receives FDA Orphan Drug Designations For The Prevention And Treatment Of Acute Graft Versus Host Disease
Wednesday, 18 Mar 2020 

March 18 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES’ ALPN-101 RECEIVES FDA ORPHAN DRUG DESIGNATIONS FOR THE PREVENTION AND TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE.  Full Article

Alpine Immune Sciences Reports Third Quarter Results
Thursday, 14 Nov 2019 

Nov 13 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES INC QTRLY LOSS PER SHARE $0.62.ALPINE IMMUNE SCIENCES INC QTRLY COLLABORATION REVENUE $289,000.ALPINE IMMUNE SCIENCES - AS OF SEPTEMBER 30, 2019, CO HAD CASH, CASH EQUIVALENTS, RESTRICTED CASH, & SHORT-TERM INVESTMENTS TOTALING $47.0 MILLION.  Full Article

Alpine Immune Sciences Says ALPN-202 Submission For Clinical Trial Authorization Anticipated By Year End 2019
Tuesday, 13 Aug 2019 

Aug 13 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES PIPELINE UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES - AS OF JUNE 30, 2019, ALPINE HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALING $55.6 MILLION.ALPINE IMMUNE SCIENCES - EXPECTS TO FUND OPERATIONS, DRIVE CLINICAL ADVANCEMENT OF ALPN-101 IN AUTOIMMUNE/INFLAMMATORY DISEASES INTO 2021.ALPINE IMMUNE SCIENCES INC - ALSO EXPECTS TO FUND OPERATIONS, DRIVE CLINICAL ADVANCEMENT OF ALPN-202 IN ONCOLOGY, INTO 2021.ALPINE IMMUNE SCIENCES INC - ALPN-202 SUBMISSION FOR CLINICAL TRIAL AUTHORIZATION ANTICIPATED BY YEAR END 2019.  Full Article

Alpine Immune Sciences Reports Q1 2019 Results, Provides Corporate Update
Thursday, 9 May 2019 

May 9 (Reuters) - Alpine Immune Sciences Inc ::QTRLY CASH & CASH EQUIVALENTS OF $41.4 MILLION VERSUS $10.7 MILLION AS OF PRIOR QUARTER .ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE $0.70.EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.Q1 EARNINGS PER SHARE VIEW $-0.69 -- REFINITIV IBES DATA.  Full Article

Alpine Immune Sciences Reports Q1 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.QTRLY NET LOSS PER SHARE $0.70.EXPECTS TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.Q1 EARNINGS PER SHARE VIEW $-0.69 -- REFINITIV IBES DATA.QTRLY CASH AND CASH EQUIVALENTS $41,437 VERSUS $10,711.  Full Article

Alpine Immune Sciences Expects To Have Sufficient Cash To Fund Operations Into 2021
Monday, 18 Mar 2019 

March 18 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2018 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES INC - AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS TOTALING $52.3 MILLION.ALPINE IMMUNE SCIENCES - EXPECT TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2021.  Full Article

Alpine Immune Sciences Reports Q3 Diluted Net Loss Per Share Attributable To Common Stockholders Of $0.88
Friday, 9 Nov 2018 

Nov 8 (Reuters) - Alpine Immune Sciences Inc ::ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.ALPINE IMMUNE SCIENCES INC QTRLY DILUTED NET LOSS PER SHAREATTRIBUTABLE TO COMMON STOCKHOLDERS $0.88.ALPINE IMMUNE SCIENCES INC - EXPECT TO HAVE SUFFICIENT CASH TO FUND OPERATIONS INTO 2020.  Full Article

BRIEF-Alpine Immune Sciences Says Anticipate Having Enough Cash To Fund Planned Operations Into 2023

* ALPINE IMMUNE SCIENCES - ANTICIPATES HAVING ENOUGH CASH TO FUND PLANNED OPERATIONS INTO 2023, EXCLUDING REVENUE FROM EXISTING PARTNERSHIPS OR NEW ARRANGEMENTS